Position of the Transparency Council – Kanuma (sebelipase alfa)

At its meeting on 8 July 2024, the Transparency Council adopted opinion No. 63/2024 on the evaluation of the drug Kanuma (sebelipase alfa) under the drug program “Treatment of patients with lysosomal acid lipase deficiency (ICD-10 E75.5 E75.6)”

Publication of the position >>